Why Regeneron’s Approval is Bad News For Esperion Therapeutics

On Friday, the FDA approved Regeneron Pharmaceuticals (REGN) cholesterol drug Praluent–which might not has been the best news for Regeneron or Esperion Therapeutics (ESPR) UBS analyst Matthew Roden explains why the approval wasn’t the best case scenario for Regeneron: Associated Press Regeneron Pharmaceuticals CEO Leonard Schleifer FDA’s approval of Regeneron/Sanofi’s (SNY) Praluent was largely expected, and [...]